Global Media Strategies -- Your Brand, Your Audience

Trimeris receives request from Arigene for extension of tender offer period

December 28, 2009 By: NCTechNews Category: Biopharmaceutical

(Durham, N.C.) Trimeris, Inc. (Nasdaq: TRMS) (“Trimeris”) has announced that in connection with the Agreement and Plan of Merger dated October 2, 2009, as amended, by and among Trimeris, Arigene Co., Ltd. and RTM Acquisition Company (“Arigene” and “Purchaser,” respectively) (the “Merger Agreement”), Arigene has requested through counsel that Trimeris consent to an extension of the expiration date of the tender offer for all of Trimeris’ outstanding shares of common stock commenced by Arigene and the Purchaser on October 19, 2009. Arigene has requested an extension of the expiration date of the tender offer to January 15, 2010.

Under the Merger Agreement, the tender offer is due to expire 5:00 p.m., New York City time, on Monday, December 28, 2009 unless the parties agree otherwise. Trimeris was informed that, unless the expiration date of the tender offer is extended as requested, Arigene and the Purchaser may not have sufficient funds and available financing to purchase all shares of Trimeris common stock validly tendered and not withdrawn as of the expiration of the offer. While Trimeris is evaluating Arigene’s request to extend the tender offer period and amend the Merger Agreement, Trimeris believes that if sufficient shares are duly tendered and not withdrawn at the scheduled expiration of the tender, all conditions to Arigene’s obligation to consummate the tender offer will be satisfied and Arigene will be obligated to purchase such tendered shares.

Trimeris will also evaluate its rights and remedies under the Merger Agreement if Arigene does not complete the purchase of shares tendered under the offer.

Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON®, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company’s website at http://www.trimeris.com.

Comments are closed.

← Triangle IT company rounds up year with heads held high
Hospitals, healthcare providers to save with new Premier agreements for operating room lights and booms →

  • Packaging Cures
    RTP-based advertising and branding firm The Marketing Machine helped overcome the issue of illiteracy among medical patients in Ghana, South Africa in designing packaging for the only manufacturer of anti-retroviral drugs in the region, creating individual icons and colors to help patients understand which drugs they needed, regardless of their ability to read.

    Broadband Stimulus
    Two grants funded by the American Recovery and Reinvestment Act are being used by MCNC to expand broadband connectivity and services throughout North Carolina and create more than 1,000 engineering and construction jobs, the organization said.

    Video: QC in Pharma Mfg


    Defense Industry Gets More Competitive
    U.S. troop level decreases and shrinking armed forces budgets will lead to increased competition and a change in business operations for military contractors in North Carolina and throughout the nation, according to defense industry contracting expert Lea Strickland, requiring a more strategic and tactical approach to developing professional, properly-designed bid proposals.

    A Leg Up for Students
    Innovative concept-to-marketplace product design and development firm Montie Design is holding a Winter 2012 Student Design Contest for aspiring product designers in community colleges, four-year colleges, or high schools from North Carolina and Virginia, starting February 1.

    getting from lab 2 line
    The leader in analytical instrumentation for the pharma manufacturing industry has named a new COO responsible for manufacturing, engineering, software development, and project management for hardware and software products such as the VTT-1000 multi-variant testing device, breaking down barriers to speeding-up the drug manufacturing pipeline and cutting-down on drug shortages.

  • Recent Headlines

















free web site traffic and promotion